Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook




 

New drug targets gene to fight skin cancer

28 September 2009

By Lorna Stewart

Appeared in BioNews 527

An early stage trial of a new drug has given hope to skin cancer patients. The phase I trial, the results of which were presented at the European Cancer Organisation and the European Society for Medical Oncology conferences in Berlin, tested the drug PLX4032 for the treatment of advanced metastatic melanoma.

The drug was given to 31 patients with advanced melanoma and with the BRAF gene mutation, which is thought to cause around 60 per cent of melanomas. The BRAF gene is involved in regulation of cell growth and PLX4032 works by suppressing this gene. All the patients involved in the trial had failed at least one previous therapy and many of them had attempted several different treatments.

At the time of the conference the authors could only report findings from 22 patients. 14 of these met the official criteria for partial response which involves the diameter of tumours shrinking by at least 30 per cent for at least a month. An additional six patients also showed some response but the authors were clear that it was too early to say whether the tumours would shrink far enough to meet the partial response criteria.

This study builds on a previous trial of PLX4032 which was aimed at finding the optimum dosage of the drug. The new trial gave all patients the optimum dose - a 960 mg pill twice a day - and reported results after 2 weeks of medication. The results of the trial are obviously exciting and potentially provide much hope for cancer patients and their families. However, the authors plan much larger scale studies before the work is published and are quick to point out that this study was only a short-term, small scale trial. Dr Paul Chapman, one of the lead researchers on the trial and an attending physician on the Melanoma/Sarcoma service at Memorial Sloan-Kettering Cancer Center, New York, US, said, 'We don't know yet how long these responses will last, and we have had patients whose cancer has progressed after initially responding; so we are putting a lot of effort in to studying the patients who do relapse, trying to understand how their tumours have become resistant. In addition, one of the main side effects we've seen is that some patients develop early, non-melanoma skin cancers such as squamous cell skin cancer. We are very vigilant about this and although they are very easy to cut out, it's something we are keeping a close eye on'.

Dr Chapman and his colleagues plan to start a phase II trial of 90 patients at the end of this year. A large phase III randomised controlled trial involving several hundred patients is also planned.

SOURCES & REFERENCES
NHS Choices | 24 September 2009
 
BBC News | 23 September 2009
 
Reuters | 23 September 2009
 
The Daily Telegraph | 23 September 2009
 
Science Daily | 24 September 2009
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

22 September 2014 - by Dr Lanay Griessner 
A skin cancer drug designed to be effective in patients whose cancer is driven by a specific gene mutation has been recommended by the National Institute for Health and Care Excellence to treat patients with advanced melanoma...
05 November 2012 - by Maria Sheppard 
A drug which prolongs life in a form of skin cancer associated with a genetic mutation has been recommended for use on the NHS...
14 March 2011 - by Dr Sarah Spain 
An international collaborative team, including Cancer Research UK scientists from the University of Dundee, has uncovered the genetic cause of a rare type of skin cancer. The condition called Ferguson-Smith disease, is also known as multiple self-healing squamous epithelioma (MSSE)...

29 June 2009 - by Dr Rebecca Robey 
A new drug for the treatment of inherited forms of breast, ovarian and prostate cancer has shown promising results in early clinical trials. The study, published in the New England Journal of Medicine, reported that the drug promoted tumour reduction and clinical improvement in advanced-stage cancer patients whilst causing fewer side effects than conventional chemotherapy....
08 June 2009 - by Dr Will Fletcher 
A new 'personalised' drug has been found to decrease the size of tumours in patients with advanced melanoma by 30 per cent. Results of an initial trial were presented at the meeting of the American Society of Clinical Oncology in Orlando, US. The results showed that the experimental treatment, a 'personalised' oral drug known as PLX4032, kept the melanoma at bay for six months. Pharmaceutical giant Roche and a privately owned company called Plexxikon Inc will carry out larger trials later thi...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust
Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation